Measuring abdominal pain in people with irritable bowel syndrome using body signals
Tests a body-signal pain index in healthy adults and adults with IBS.
Key facts
- Who runs it
- University of Connecticut
- Where
- Storrs, United StatesSee the site
- Trial code
- Registry title
- Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 8 Sept 2025
- Expected to end
- 28 Feb 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- IBS-PPSM intervention
- Record updated
- 15 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome (IBS) who currently have belly pain. It tests a self-management program and wearable sensors that record body signals linked to pain.
- Age
- 18-50 years old
- Sex
- Men and women
- Disease stage
- IBS diagnosed by a healthcare provider using Rome-III or -IV criteria, with current abdominal pain.
- Earlier treatment
- People who regularly use opioids cannot join.
Main reasons for not taking part
- Other long-term pain not usually linked to IBS, such as nerve damage from diabetes, muscle pain or low back pain
- Celiac disease or inflammatory bowel disease
- Diabetes mellitus or serious mental health conditions
- Being pregnant or within 3 months after giving birth
- Regular use of opioids or illegal drugs
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants need to be diagnosed with IBS by a healthcare provider according to Rome-III or -IV criteria, with a current report of abdominal pain
- Men and women 18-50 years old
- Able to read and speak English
- Daily access to a computer with internet access
Who cannot take part
- Celiac disease or inflammatory bowel disease
- Diabetes mellitus; d) Serious mental health conditions
- Participants who have had COVID-19 should be fully recovered, and will be asked if their medical provider has made any restriction on activities
- Other chronic pains that are usually not comorbid with IBS, e.g., diabetic neuropathy, myofascial pain, low back pain, peripheral neuropathy etc
- Women during pregnancy or within 3 months post-partum period
- Self- reported Regular use of opioids or other illicit substances
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in United States
- Vernon Cottage, Depot CampusStorrs, United StatesContact: Maria GrozaTaking people
About the trial
What the trial wants to find out
The objectives of the study are to 1) Conduct telemetric biosignals (EDA, ECG, and EMG) recording in healthy controls and IBS participants experiencing cutaneous and visceral pain; and 2) Validate the OIME index as a biomarker for quantifying pain in IBS participants and its capability to assess the treatment of IBS pain via an ambulatory trial.
The 2 groups in the trial
- IBS-PPSM intervention groupTreatment being tested
After the baseline visit, the IBS-PPSM group will receive 10 video modules focused on IBS knowledge and self-management skills plus one-on-one consultation with a nurse for personalized advice about self-monitoring, diet, sleep, and goal setting. The IBS-PPSM group will be taught to use the abdominal belt/smart watch system for daily recording of bio-signals and voluntary report of episodes of visceral pain. We will follow up with all participants 4 weeks after enrollment, in a final lab visit, and measure primary outcomes to compare to the baseline data.
Treatment: IBS-PPSM intervention
- IBS-control groupNo study treatment, for comparison
The IBS-control group will not receive pain self-management intervention. Participants will be taught to use the abdominal belt/smart watch system for daily recording of bio-signals and voluntary report of episodes of visceral pain. We will follow up with all participants 4 weeks after enrollment, in a final lab visit, and measure primary outcomes to compare to the baseline data.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- OIME - Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain
- Plain-language title
- Measuring abdominal pain in people with irritable bowel syndrome using body signalsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06381921, who can take part
- Record updated
- 15 September 2025